Before the GLP-1 boom of recent years, the pharmaceutical industry had begun to shift away from blockbuster drugs towards ...

SanegeneBio, a clinical-stage biotechnology company developing RNAi therapeutics, entered a global research and licensing ...

Under the agreement Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value right (CVR) entitling holders to additional payments of up to ...

Lilly gains worldwide exclusive rights to MeiraGTx AAV-AIPL1 program for the treatment of Leber congenital amaurosis 4.

Eli Lilly and Co. has appointed two new Executive Committee members and has expanded other senior leaders’ roles to support the company in its next wave of growth.

Stewart will lead integration of technology and process transformation initiatives across Avid's development and manufacturing network.